Loading…
Maker of a wearable cardioverter defibrillator that monitors and treats patients at risk of sudden cardiac arrest.
Maker of a wearable cardioverter defibrillator that monitors and treats patients at risk of sudden cardiac arrest.
Rents the wearable device to patients for a prescribed period, usually billing their health insurers rather than the patient, so insurer coverage decisions matter as much as doctor adoption. Each prescription lasts only until the patient's heart recovers or a permanent implant is fitted, so revenue depends on a steady flow of newly prescribed patients.
In one line: A newer rival to ZOLL's LifeVest wearable defibrillator.
Moat: narrow (IP / patents, regulatory licence). One of few FDA-cleared wearable defibrillators, competing directly with the long-established ZOLL LifeVest.
Headquarters: Kirkland, Washington · Founded: 2012 · Employees: 443
Size Kestra Medical Technologies (KMTS) is a United States Health Care company (Medical Specialties) with a market value of $1.72B, the 1892nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $28.80 on 6 Nov 2026.
Performance Over six months the shares gained 36.8%, against -4.0% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 60.7% over the last twelve months (peer median +9.3%); the operating margin is -134.5% (peer median 12.7%).
Valuation It trades at 14.9× enterprise value to sales against a peer median of 4.1× (2nd most expensive of 21).
Capital Return on invested capital runs 120.6 points below its cost of capital (7.1% WACC).
Short interest Short interest is 5.8% of the free float (15 Oct 2026).
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $107M | $95.1M | $59.8M | $27.8M | $7.63M |
| Revenue growth | — | +59% | +115% | +265% | — |
| Gross profit | $57.5M | $48.9M | $24.2M | $362,000 | -$10.7M |
| EBITDA | -$134M | -$126M | -$98.4M | -$73.5M | -$75.6M |
| Net income | -$150M | -$132M | -$114M | -$94.1M | -$84.2M |
| Free cash flow | -$123M | -$117M | -$101M | -$84.7M | -$85.1M |
| Capital expenditure | $35.5M | $35.4M | $23.6M | $12.5M | $15.5M |
| Total debt | $76.4M | $46.8M | $44.3M | $45.2M | $39.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kestra Medical Technologies KMTS | $1.72B | +37% | +61% | -134% | 14.9× | n/a |
| Medtronic MDT | $130B | +35% | +10% | 20% | 4.0× | 8.6% |
| Boston Scientific BSX | $62.0B | -21% | +9% | 21% | 3.5× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KMTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.8% | +0.3% | 7th highest of 21 |
| 6-month return | +36.8% | -4.0% | 5th highest of 20 |
| Distance from 52-week high | -9.7% | -23.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +60.7% | +9.3% | 2nd highest of 21 |
| Operating margin | -134.5% | 12.7% | lowest of 21 |
| EV / Sales | 14.9× | 4.1× | 2nd most expensive of 21 |
| ROIC minus cost of capital | -120.6 pp | +2.3 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | 14.9× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 2.3× | 12.5% | +7.4% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | 13.0× | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 8.2× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 3.2× | 18.1% | +25.8% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 21.4× | 17.9% | +12.7% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 2.2× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 1.5× | -3.2% | -1.0% |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 3.2× | 18.8% | +14.5% |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 7.9× | n/a | n/a |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | 11.7× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 4.9× | 22.0% | +22.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 1.0× | -2.1% | +3.3% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 5.5× | n/a | n/a |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 5.9× | 3.1% | +23.4% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 7.6× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 6.3× | 2.9% | +14.0% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 1.8× | 30.9% | +51.2% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 2.1× | 10.8% | +18.3% |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 1.3× | 22.3% | -6.0% |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 1.1× | 10.2% | +1.9% |